Integrated Histopathological, Lipidomic, and Metabolomic Profiles Reveal Mink Is a Useful Animal Model to Mimic the Pathogenicity of Severe COVID-19 Patients

The authors demonstrated that minks were largely permissive to SARS-CoV-2, characterized by severe and diffuse alveolar damage, and lasted at least 14 days post inoculation.
[Signal Transduction and Targeted Therapy]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase II Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovirâ„¢ in the Treatment of Hospitalized COVID-19 Patients

Todos Medical, Ltd. announced positive interim data for its Tollovirâ„¢ oral antiviral 3CL protease inhibitor Phase II clinical trial for the treatment of hospitalized (severe and critical) COVID-19 patients.
[Todos Medical, Ltd.]
[zotpress userid=” items=’nan’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Extracellular Vimentin Is an Attachment Factor That Facilitates SARS-CoV-2 Entry into Human Endothelial Cells

The authors described the identification of vimentin, an intermediate filament protein widely expressed in cells of mesenchymal origin, as an important attachment factor for SARS-CoV-2 on human endothelial cells.
[Proceedings of the National Academy of Sciences of the United States of America]
[zotpress userid=” items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

SARS-CoV-2 Infection Triggers Paracrine Senescence and Leads to a Sustained Senescence-Associated Inflammatory Response

In cultured human cells or bronchial organoids, SASR-CoV-2 infection-induced senescent cells expressed high levels of a series of inflammatory factors known as senescence-associated secretory phenotypes 4 in a sustained manner, even after SARS-CoV-2 was no longer detectable.
[Nature Aging]
[zotpress userid=’7992332′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Matrix Metalloproteinases (MMP) 3 and 9 as Biomarkers of Severity in COVID-19 Patients

Investigators studied serum MMP3 and MMP9 as potential biomarkers of COVID-19 severity, in 108 hospitalized patients with different World Health Organization severity stage and in 48 controls.
[Scientific Reports]
[zotpress userid=’7992332′ items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

The SARS-CoV-2 Monoclonal Antibody Combination, AZD7442, Is Protective in Non-Human Primates and Has an Extended Half-Life in Humans

The authors described AZD7442, a combination of two mAbs, AZD8895 and AZD1061, that simultaneously bound to distinct, nonoverlapping epitopes on the spike protein receptor binding domain to neutralize SARS-CoV-2.
[Science Translational Medicine]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Vaccination before or after SARS-CoV-2 Infection Leads to Robust Humoral Response and Antibodies That Effectively Neutralize Variants

Investigators measured neutralizing antibody responses from 104 vaccinated individuals, including those with breakthrough infections, hybrid immunity, and no infection history.
[Science Immunology]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Vasomune and AnGes Announce First Patient Enrolled in Phase IIa Clinical Study Evaluating AV-001 for the Treatment of Severe COVID-19 Disease

Vasomune Therapeutics, Inc. announced it has dosed the first patient in the Phase IIa clinical study to evaluate AV-001 in patients hospitalized with severe COVID-19 disease.
[Vasomune Therapeutics, Inc.]
[zotpress userid=” items=’BBBBBBBB’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

B Cell Depletion and SARS-CoV-2 Vaccine Responses in Neuroimmunologic Patients

Scientists investigated prospectively humoral and cellular responses to SARS-CoV-2 mRNA vaccination in 82 patients with neuroimmunologic disorders on anti-CD20 therapy and 82 age- and sex-matched healthy controls.
[Annals of Neurology]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

SARS-CoV-2 Targets the Lysosome to Mediate Airway Inflammatory Cell Death

Emerging evidence suggests that SARS-CoV-2 could trigger pyroptosis, a form of inflammatory programmed cell death characterized by the activation of inflammasomes and caspase 1 and the formation of transmembrane pores by gasdermin D.
[Autophagy]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

SARS-CoV-2 Breakthrough Infections Elicit Potent, Broad and Durable Neutralizing Antibody Responses

The authors demonstrated that breakthrough infections induced serum binding and neutralizing antibody responses that were markedly more potent, durable and resilient to spike mutations observed in variants than those in subjects who received only two doses of vaccine.
[Cell]
[zotpress userid=” items=’AAAAAAAA’ style=’apa’ cite=’yes’]
AbstractFull Article
Bookmark

No account yet? Register

Share
Share